Ribociclib plus endocrine therapy led to a statistically significant improvement in PFS compared with placebo plus endocrine therapy in participants with tumor progression following a CDK 4/6 inhibitor
Pyrotinib, a second-generation, irreversible anti-human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, plus nab-paclitaxel showed promising anti-tumor activity in patients with HER2-positive advanced or metastatic breast cancer.
Results of the DESTINY-Breast04 study, presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated significant survival benefit with trastuzumab deruxtecan versus standard of care chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer.
Research presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting revealed prognostic factors that impacted overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and brain metastases
In ESMO Open, Enrique Grande, MD, and collaborating researchers published findings from the IMMUNOSUN trial on the safety and efficacy of sunitinib as a pure second-line treatment for patients with metastatic renal cell carcinoma (mRCC).